Peloton Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing first-in-class oral medicines for cancer and other serious conditions, announced that Timothy P. Coughlin, former Chief Financial Officer of Neurocrine Biosciences, Inc., and Thilo Schroeder, Ph.D., Partner at Nextech Invest, Ltd. and former Peloton Board Observer, have been appointed to its Board of Directors